A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with advanced/metastatic pancreatic cancer, and determine the RP2D for SHR-1701 in the combined regimen.
Pancreatic Cancer
DRUG: SHR-1701
RP2D, Recommended Phase 2 Dose of SHR-1701, Up to week 3|ORR, Objective Response Rate, Up to approximately 6 months
Clinically significant toxicity, above grade 3 AEs, Up to week 3|OS rate, 9-month-overall survival rate, From the start of treatment to 9 months|AEs+SAEs, Adverse Events and Serious Adverse Events, from the first drug administration to within 90 days for the last SHR-1701 dose|PFS, Progression-Free-Survival, Up to approximately 6 months|DCR, Disease Control Rate, Up to approximately 12 months|OS, OS is the time interval from the start of treatment to death due to any reason or lost of follow-up, up to 2 years
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with advanced/metastatic pancreatic cancer, and determine the RP2D for SHR-1701 in the combined regimen.